Report copyright - VedolizumabShould Not Be Used as a First Line Biologic in IBD...– A faster biologic agent? • Increased cost, immunogenicity. What if it doesn’t work?: Cannot dose‐optimize
Please pass captcha verification before submit form
Please pass captcha verification before submit form